FSP Trends Report 2022
2022 drug development outsourcing trends: A shift to functional service partnerships
As the drug development industry evolves, the PPD™ clinical research business of Thermo Fisher Scientific is seeing a significant shift to outsourcing, specifically toward the use of functional service partnerships (FSPs). In this report, our experts weigh in on questions surrounding:
- Key industry challenges that have contributed to this shift to outsourcing
- FSP market size and percentage of outsourcing observed
- Ranked benefits of working with an FSP model
With these insights, drug developers will better understand what’s driving the shift to FSP services and why they should consider FSP solutions as an outsourcing model.
Learn more about our Functional Service Partnership solutions.